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Abstract
Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown
robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and
renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor infiltrating lymphocytes, PD-L1 status,
and mutational load may be equally or even more important in predicting clinical benefit from PD-1 pathway blockade
than tumor histology. This case of a patient with concurrent metastatic melanoma and metastatic RCC, both of which
were controlled for more than a year after a single dose of the anti-PD-1 antibody pembrolizumab, illustrates
the potential to simultaneously treat distinct immunogenic tumors with anti-PD-1 agents.
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Background
Immune checkpoint blockade using monoclonal anti-
bodies directed against negative regulators such as
cytotoxic lymphocyte antigen-4 (CTLA-4) and pro-
grammed death 1 (PD-1)/programmed death ligand 1
(PD-L1) has emerged as a powerful strategy in the
treatment of different cancer types [1–3]. Both CTLA-
4 and PD-1 are cell surface receptors that negatively
regulate the immune response and their blockade can
induce or enhance anti-tumor T cell activity. The anti-
CTLA-4 monoclonal antibody ipilimumab demon-
strated a survival benefit in Phase III studies for the
first time in patients with advanced melanoma [2, 4],
leading to approval in several countries. Durable tumor
responses in patients with advanced melanoma being
treated with ipilimumab yielded a plateau in the sur-
vival curve at 21 % 3 years out from study initiation
[5]. Inhibition of the PD-1/PD-L1 pathway showed ob-
jective response rates of up to 40 % and superior overall
survival when compared to ipilimumab in advanced mel-
anoma [6]. Strikingly, as opposed to the relatively modest
anti-tumor activity of ipilimumab outside of melanoma,
PD-1 pathway inhibition is efficacious against a wide
spectrum of solid and hematological malignancies includ-
ing RCC, non-small cell lung cancer, bladder cancer, and
Hodgkin’s lymphoma. There is evidence that tumor
characteristics such as the presence of an immune cell
infiltrate, expression of PD-L1 on tumor and/or immune
cells, and an elevated mutational load with corresponding
expression of neoantigens are predictive of anti-tumor
activity with PD-1 pathway inhibition [7–10]. The broad
anti-tumor activity of PD-1 pathway blockade suggests
that it may be effective against different tumors present in
one individual. These considerations may be critical in
designing a treatment plan for a patient with metastases
from different primary tumors, which poses a particular
challenge in current cancer therapeutics. Here, we present
a patient with concurrent metatstatic melanoma and
RCC who achieved disease control of both malignan-
cies after a single dose of the anti-PD-1 monoclonal
antibody pembrolizumab.* Correspondence: Patrick_Ott@dfci.harvard.edu
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Case presentation
A 73-year-old man was diagnosed with T1a melanoma
arising from the right shoulder in 2009. He underwent a
wide excision and sentinel lymph node biopsy. Pathology
review revealed a 1.64 mm melanoma, anatomic level deep
III/early IV, no ulceration, 1 mitosis/mm2. Four right axil-
lary sentinel lymph nodes were negative for involvement
with melanoma. In September 2013, after experiencing
hematuria, the patient underwent a cystoscopy followed by
transurethral resection of a bladder tumor (TURBT), which
revealed a low-grade urothelial carcinoma with no evidence
of bladder invasion. He is a lifelong non-smoker. A staging
computerized tomography (CT) scan revealed two right
lower lobe lung nodules (2.7 cm and <1 cm), and a 6.3 cm
tumor in the left kidney. A positron emission tomography
computerized tomography (PET/CT) in November 2013
(Fig. 1) showed enlarged mediastinal lymph nodes in
addition to FDG uptake in the lung nodules and a complex
left kidney mass. A mass in the thoracic spine (T3 vertebra)
and a small focus of uptake in the right sacral ala were also
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Fig. 1 Timeline of events and treatment. CT = computerized tomography. PET = positron emission tomography. RLL = right lower lobe. RCC = renal
cell carcinoma
Fig. 2 a PET CT demonstrating FDG uptake in an enlarged mediastinal lymph nodes, small right lower lobe lung nodule, exophytic heterogenous
mass in left kidney and a 3.5 × 3.2 cm vertebral mass at T3 with SUV of 11.4. b Enhanced CT view of the T3 vertebral mass
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noted (Fig. 2). A biopsy of the T3 vertebral lesion was per-
formed and pathologic review demonstrated RCC. A core
needle biopsy of one of the right lower lobe lung nodules
was also performed and unexpectedly revealed recurrent
metastatic melanoma (Fig. 3). In December 2013, a brain
MRI showed a subcentimeter left temporal metastasis. The
patient received radiation to the T3 vertebral metastasis
and stereotactic radiosurgery to the brain metastasis.
While weighing the treatment options for these two
cancers, although our initial thoughts were to focus on
the more aggressive melanoma (BRAF and NRAS wild
type), we were motivated to design a therapy regimen
that could yield efficacious responses against both can-
cers. Bevacizumab, the anti-Vascular Endothelial Derived
Growth Factor (VEGF) directed monoclonal antibody
approved for use in renal cell carcinoma, has some effi-
cacy in advanced melanoma and was found to be safe
and potentially synergistic with ipilimumab [11, 12]. The
urothelial cancer was not addressed therapeutically
because of the metastatic melanoma and RCC taking
precedence. Based on this data, the patient received one
cycle of ipilimumab at the standard dose of 3 mg/kg.
Following insurance approval, he then received a cycle
of ipilimumab in combination with bevacizumab 15 mg/
kg every 3 weeks. Shortly after receiving the combin-
ation, the patient presented with a left sided headache,
blurred vision in the left eye, and left eyelid ptosis. A
brain MRI revealed a subacute hemorrhage at the site of
the previously irradiated left temporal metastasis. A tem-
poral artery biopsy was negative for temporal arteritis. The
remainder of ipilimumab therapy (3rd and 4th dose) was
administered without concurrent Bevacizumab given the
concern that VEGF inhibition may have possibly contrib-
uted to the brain hemorrhage. The ipilimumab treatment
course was also complicated by immune-related hypophy-
sitis resulting in adrenal insufficiency, which was success-
fully treated with hydrocortisone.
Serial PET/CTs showed progressive disease in April
2014. Repeat PET/CT performed in July of 2014 once
again revealed disease evolution with increased FDG avid-
ity of a dominant right lower lobe lung mass, increased
size and avidity of a right adrenal lesion, and increased
FDG avidity of the left sided renal mass. Based on these re-
sults and the availability on an Expanded Access Program,
treatment with the anti-PD-1 antibody pembrolizumab at
2 mg/kg every 3 weeks was initiated in July of 2014. After
Fig. 3 Pathology of T3 vertebral mass and right lower lobe lung lesions. Pathology of the T3 vertebral mass biopsy represents a metastasis from
renal cell carcinoma, the lung lesion is consistent with a metastasis from melanoma. (1) Immunohistochemistry markers of the T3 vertebral mass
and the right lower lobe (RLL) lung nodule. (2) T3 vertebral lesion: a. low power b. high power c. CAM5.2 d. Pax-8 (3) RLL lesion: a. high power b.
Cytokeratin (CK7) c. S100 d. Melan-A e. HMB45
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one dose, the patient developed grade 3 transaminitis
(ALT > 7x ULN, AST >11x ULN, total bilirubin normal),
prompting discontinuation of treatment due to presumed
immune-related hepatitis. Intravenous solumedrol was ad-
ministered for the treatment of immune-related hepatitis.
A liver biopsy performed six days into the steroid taper
(prednisone 80 mg BID for the six days prior to biopsy)
showed pathological features compatible with but not
diagnostic of immune-related hepatitis. Liver function
tests normalized fifteen days after the initial diagnosis and
remained within reference range after completion of a
four-week prednisone taper.
Restaging CTs of the chest, abdomen, and pelvis per-
formed in September 2014 demonstrated dramatic re-
duction in size of several lung metastases, while others
remained stable. The right adrenal lesion, several mes-
enteric nodules, and a subcutaneous nodule on the left
anterior abdominal wall were all substantially smaller
in size. The left renal mass remained stable. Serial CTs
of the chest, abdomen, and pelvis in November 2014,
February 2015, May 2015, and August 2014 showed
continued decrease in tumor size consistent with a partial
response to treatment for a duration of 14 months (Fig. 4).
Most recently, a chest, abdomen, and pelvic CT in
November of 2015 showed two new subcentimeter pul-
monary lesions and a satellite nodule in the primary renal
cell cancer. The patient is currently undergoing re-
induction therapy with pembrolizumab.
Conclusion
We describe a patient with concurrent biopsy-proven
metastatic melanoma and RCC who was treated with one
dose of pembrolizumab that was complicated by immune-
related hepatitis but nevertheless lead to a durable tumor
response in both melanoma and RCC.
While the presence of two distinct metastatic processes
was established by biopsy (melanoma in the lung and
RCC in the spine at level T3), the contribution of each
tumor to the overall metastatic burden cannot be deter-
mined. However, since at least one (and likely more) lung
lesion(s) represent melanoma and the left renal lesion rep-
resent RCC by imaging criteria, ongoing disease control of
both cancers was evident on serial imaging. It is notable
that the patient developed immune-related hepatitis after
only one dose of pembrolizumab. Immune-related toxicity
may be associated with a favorable outcome in patients
treated with CTLA-4 and/or PD-1 inhibition [13].
Multiple primary cancers, which is defined as the
development of another primary cancer after diagnosis
of an initial one (index cancer) in a given individual, is a
relatively common occurrence. Interestingly, urinary
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Fig. 4 a PET CT images of the mediastinal mass, pulmonary lesion and renal mass. Left column: Pre- pembrolizumab; right column: 8 weeks after
administration of one dose of pembrolizumab. There is near complete involution of the anterior mediastinal mass and a decrease in size of the
pulmonary lesion. The size of the renal mass is unchanged. b Size (cm) on axial imaging (CT or PET/CT) of renal, mediastinal and dominant right
pulmonary nodule over time. The last scan showed two new subcentimter pulmonary metastases and increased size of a soft tissue component
of the left renal mass
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patients with multiple primary cancers (18 %), whereas
10 % of patients with RCC and melanoma, respectively de-
velop a second primary [14]. No reliable data are available,
to our knowledge, on frequencies of multiple primaries
that have metastasized concurrently such as in our pa-
tient. It is interesting in this context that the patient’s
diagnosis of a localized low grade urothelial carcinoma of
the bladder immediately preceded the patient’s diagnosis
of metastatic melanoma and RCC. While the non-muscle
invasive bladder cancer lead to the diagnosis of melanoma
and RCC in our patient, it appears unlikely that the blad-
der cancer contributed to the metastatic disease burden in
this patient. Since bladder cancer has also been found to
be responsive to PD-1 pathway inhibition, the possibility
that a third solid tumor may also have been controlled by
PD-1 blockade in our patient is nevertheless an intriguing
consideration [8].
PD-1 blockade reverts the PD-1 receptor-mediated dys-
functional state of effector memory T cells that have infil-
trated the tumor into an active, functional state, thereby
enabling tumor cell killing. These T cells are presumably
endogenously primed and specific for antigens expressed
on the respective tumor they traffic into. It therefore
appears more likely that these T cells recognize tumor an-
tigens that are distinct between the melanoma and the
RCC rather than shared antigens. Although the immune
response may be distinct in RCC and melanoma, a certain
percentage of these tumors are immunogenic and there-
fore potentially responsive to immune checkpoint block-
ade [15]. This case illustrates that despite these distinct
immune responses, PD-1 inhibition may be a suitable
treatment option for patients with concurrent immune-
responsive cancers.
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